HOME >> MEDICINE >> NEWS
Trial shows malaria vaccine could protect young children from disease for 18 months

The RTS, S/AS02A vaccine could protect young African children against a range of clinical disease caused by the malaria parasite for at least 18 months, concludes a randomised trial published online today (Tuesday November 15, 2005) by The Lancet.

Early trials of the RTS, S/AS02A vaccine have shown that the vaccine is safe, well tolerated, and can trigger an immune response. In one of the trials, involving over 2000 Mozambican children aged 1-4 years, Pedro Alonso (University of Barcelona, Spain) and colleagues found that after 6 months' follow-up the vaccine reduced the risk of clinical malaria by 30%, delayed time to first infection by 45%, and reduced the risk of severe malaria by 58%. In the latest study the investigators followed-up the children for a further 12 months. They found that the efficacy of the drug did not wane and that protection against clinical malaria lasted for at least 18 months after vaccination. The study shows that the vaccine reduces the risk of clinical malaria by 35% and nearly halves the risk of severe malaria over a period of 18 months.

Professor Alonso states: "Our results show that the RTS,S/AS02A candidate malaria vaccine confers partial protection for at least 18 months against a range of clinical diseases caused by P falciparum in children living in a rural malaria endemic area of African The combination of sustained protection together with substantial prevention of the severe forms of malaria marks RTS, S/AS02A as a promising vaccine candidate and strongly suggests that malaria vaccines have an important role as future public-health instruments."

The publication coincides with a presentation at the Fourth Multilateral Initiative on Malaria Pan-African Malaria Conference 2005 in Yaounde, Cameroon.


'"/>

Contact: Joe Santangelo
j.santangelo@elsevier.com
212-633-3810
Lancet
15-Nov-2005


Page: 1

Related medicine news :

1. Trial stops after stroke and mortality significantly reduced by blood
2. Trials underway for essential new TB vaccine
3. Trial shows circulating tumor cells predict how prostate cancer patients do with chemotherapy
4. ENDEAVOR III Trial reports key findings on new-generation stent
5. NIH names Clinical Trial Units for the Microbicide Trials Network
6. Clinical Trials Units selected for newly restructured HIV/AIDS research networks
7. The Public Library of Science launches the new open access journal PLoS Clinical Trials
8. Trial shows vaccine against cervical cancer provides long-term protection
9. Trial demonstrates new drugs effectiveness against psoriasis
10. Trial at Jefferson shows new drug may help cancer patients who need stem cell transplants
11. Second implant of US Pilot Trial achieved

Post Your Comments:
(Date:7/30/2015)... ... July 30, 2015 , ... Case Mason ... services for consumer brands, recently completed a consolidation of all of its production ... company operated out of two separate locations situated 11 miles apart. , The ...
(Date:7/29/2015)... ... July 30, 2015 , ... Macro Wealth Management (MWM) Presidents have ... a Lifetime program by encouraging their clients to donate their MWM planning fees to ... Mart McClellan and Tim Streid, who see charitable giving as an important part of ...
(Date:7/29/2015)... Washington D.C. (PRWEB) , ... July 29, 2015 , ... ... 2016 average monthly Medicare Part D premium is expected to remain stable at $32.50, ... said. , “The popular Part D program continues to be a bright spot in ...
(Date:7/29/2015)... (PRWEB) , ... July 29, 2015 , ... ... organizations that seek to help with the problems of substance abuse that face ... Against Drunk Driving (MADD) to come to their rehabilitation center. The facility, located ...
(Date:7/29/2015)... ... July 29, 2015 , ... The power of social ... that give small businesses financial support, social connections can be used to accomplish ... health management programs, unveiled today a downloadable resource for employers that provides guidance ...
Breaking Medicine News(10 mins):Health News:Case Mason Consolidates Operations to Larger Facility for Increased Efficiency, Improved Service 2Health News:Case Mason Consolidates Operations to Larger Facility for Increased Efficiency, Improved Service 3Health News:Smile for a Lifetime (S4L) Partners with Macro Wealth Management (MWM) Helping More Children Get Braces 2Health News:MADD Victim Services Specialist Visits A Forever Recovery Rehabilitation Facility 2Health News:StayWell Unveils Employer Guide to Developing Effective Employee Wellness Champion Networks 2Health News:StayWell Unveils Employer Guide to Developing Effective Employee Wellness Champion Networks 3Health News:StayWell Unveils Employer Guide to Developing Effective Employee Wellness Champion Networks 4
(Date:7/29/2015)... July 29, 2015  Unilife Corporation ("Unilife" or the ... developer, manufacturer and supplier of injectable drug delivery systems, ... that provides the Company with flexibility and control to ... has signed an equity purchase agreement for up to ... a Chicago -based institutional investor, which ...
(Date:7/29/2015)... July 29, 2015  Ascendis Pharma A/S (Nasdaq: ... its innovative TransCon technology to address significant unmet medical ... call on July 30, 2015, at 9:00 a.m. Eastern ... 2 pediatric study of once-weekly TransCon Growth Hormone. The ... results before the market opens on July 30, 2015. ...
(Date:7/29/2015)... 2015 Varian Medical Systems, Inc., (NYSE: VAR ... European subsidiaries, agreed to acquire Claymount, a privately-held, ... for X-ray imaging equipment manufacturers. Varian,s subsidiary in ... in cash for Claymount. The transaction is expected to ... one of the world,s leading suppliers of high voltage ...
Breaking Medicine Technology:Unilife Announces Multifaceted Financing Strategy 2Unilife Announces Multifaceted Financing Strategy 3Unilife Announces Multifaceted Financing Strategy 4Unilife Announces Multifaceted Financing Strategy 5Ascendis Pharma A/S to Report Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone and Host Conference Call on Thursday, July 30, 2015 at 9:00 a.m. Eastern Time 2Varian Medical Systems Acquiring Claymount to Expand Imaging Components Portfolio 2Varian Medical Systems Acquiring Claymount to Expand Imaging Components Portfolio 3Varian Medical Systems Acquiring Claymount to Expand Imaging Components Portfolio 4
Cached News: